Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNR-086 vs Ilaris in Adult-onset Still's Disease
NCT06497491Phase 3Completed
- Sponsor
- Generium
- Start
- Dec 2023
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of GNR-086 in adult-onset Still's disease (AOSD), sponsored by Generium. Started Dec 2023; status: completed.
02
Drugs
GNR-086
03
Conditions
adult-onset Still's disease (AOSD)
Beyond the preview
Go deeper on NCT06497491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06497491.